Join us for our hybrid symposium, in conjunction with Breast Cancer Awareness Month, 2022.
‘From the Breast Cancer Lab to You’ is our annual community update on breast cancer and includes presentation from Garvan and international research leaders, oncologists, patients and funding organisations.
Presentations include updates on research advances in new treatments, drug resistance and metastasis, as well as new clinical trials.
Date: Friday, 7th October 2022
Time: 2:00pm – 3:30pm (AEDT)
Venue: 384 Victoria St, Darlinghurst NSW 2010 or via Zoom.
Spaces are limited in the Auditorium so registration is essential.
Meet our speakers
Prof Elgene Lim
Prof Elgene Lim is a medical oncologist and researcher with a focus on breast cancer research and treatment.
Prof Elgene Lim is the Principal Cancer Theme Lead at the Faculty of Medicine, UNSW Sydney, and the inaugural National Breast Cancer Foundation Endowed Chair.
Prof Lim's research findings the identification of the culprit cells in carriers of the BRCA1 mutant gene, a hereditary breast cancer syndrome. He completed his medical and oncology training, and doctoral research in Melbourne. Findings from his PhD research,had a major impact on the identification of the culprit cells in carriers of the BRCA1 mutant gene, a hereditary breast cancer syndrome. He furthered his research and clinical training at the Dana-Farber Cancer Institute and Harvard Medical School through fellowships from the Fulbright Foundation, National Health and Medical Research Council of Australia, and Royal Australasian College of Physicians.
A/Prof Alex Swarbrick
A/Prof Alex Swarbrick is a Principal Research Fellow and Head of Garvan’s Tumour Progression Laboratory.
In 2012, A/Prof Swarbrick was appointed co-Head of the Breast Translational Oncology Program in The Kinghorn Cancer Centre. He is an Associate Professor at UNSW and an NHMRC Senior Research Fellow. A/Prof Swarbrick is the immediate-past convenor of the Lorne Cancer Conference, Australia's pre-eminent multi-disciplinary cancer research conference & the Australian Translational Breast & Prostate Cancer Symposium. He serves on the Cancer Research Committee of the Cancer Council NSW.
Dr Liz Caldon
Dr Liz Caldon leads the Replication and Genome Stability research group at Garvan.
She studies the way that faulty DNA replication and cell division can alter the fate of a cancer cell. Established in 2013, Dr Caldon's group works towards understanding the way that cancer cells evolve due to the selective pressure of therapeutic drugs and cancer driver genes called oncogenes.
In her PhD studies, Dr Caldon investigated the interaction between hormone signalling and proliferative control of breast cancer cells. The primary goal of her research at Garvan is to understand the evolution of hormone therapy resistance in breast cancer, which is a major cause of breast cancer-related death. Based on their findings on the multistep acquisition of hormone therapy resistance, Liz and her team are focussed on translating knowledge about fundamental breast cancer biology and evolution into targetable therapies that provide clinical benefit.